Latest News

In a new paper, Pramod Mistry and colleagues describe a thriving program that provides therapies to people with rare diseases.

The American College of Neuropsychopharmacology (ACNP) will award Kristen J. Brennand, PhD, its 2022 Daniel H. Efron Research Award for outstanding basic research contributions to neuropsychopharmacology.

Most families with autosomal dominant polycystic kidney disease (ADPKD) possess a genetic mutation in PKD1, that impacts the protein polycystin-1 (PC1). In a new article published online Friday, October 21, 2022, in the Journal of the American Society of Nephrology, a Yale team led by Stefan Somlo, MD and Sorin Fedeles, PhD, MBA demonstrated that the activation of the transcription factor XBP1 in vivo can improve the residual function of a mutant form of PC1, thereby decreasing the severity of ADPKD.

Stem cell-derived neurons from combat veterans with and without post-traumatic stress disorder (PTSD) provide insights into how genetics can make someone more susceptible to developing PTSD following trauma exposure, according to a study conducted by scientists from several research institutions, including Yale School of Medicine.

Brennand's research integrates expertise in genetics, neuroscience, and stem cells to identify the mechanisms that underlie brain disease,

Arya Mani, MD, FACC, FAHA, director of the Yale Medicine Cardiovascular Genetics Program, says certain cardiovascular diseases are significantly impacted by genes.

Yale School of Medicine's Ob/Gyn Chair Hugh Taylor, MD, was a leader of a clinical trial for a drug that could sharply advance uterine fibroid treatment.

Renato Polimanti, PhD, assistant professor of psychiatry at Yale School of Medicine, has received a 3-year grant from the National Institute of Mental Health (NIMH) to evaluate the association of internalizing disorders with the risk, onset, and vulnerability of COVID-19.

The use of AI to analyze complex datasets presents a groundbreaking opportunity to answer questions previously beyond the reach of biomedical researchers. The Bridge2AI program will support the creation of accessible, AI-ready datasets that can be used multiple times for a range of medical challenges.